950210 fundamentals
PRESTIGE BIOPHARMA LIMITED KDR financial statements, including revenue, expenses, and profit
The total revenue of 950210 for the last quarter is 3.16 B KRW, and it's 42.32% higher compared to the previous quarter. The net income of Q2 25 is -13.36 B KRW.
Q3 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: KRW
Q3 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
TTM